LBRX insider transaction filings
LB PHARMACEUTICALS INC — 27 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-03. Screen LBRX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-03 | 4 | Deep Track Biotechnology Master Fund, Ltd. — 10% owner Deep Track Capital, LP — 10% owner KROIN DAVID — 10% owner | Purchase (P): 286,205 (derivative) @ $34.94 | EDGAR |
| 2026-06-05 | 4 | Luse Rebecca — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Lenz Robert A. — Director | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Kane William P Jr — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Hemrajani Rekha — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Nussbaum Ran — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Garland J. Scott — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | RUFFOLO ROBERT R — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Lenz Robert A. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-10 | 4 | Deep Track Biotechnology Master Fund, Ltd. — 10% owner Deep Track Special Opportunities Fund, LP — 10% owner Deep Track Capital, LP — 10% owner KROIN DAVID — 10% owner | Purchase (P): 378,444 (derivative) @ $21.17 · Purchase (P): 93,925 (derivative) @ $21.17 | EDGAR |
| 2025-12-11 | 4 | Pai Panandiker Kaya Kamlesh — Chief Commercial Officer | Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2025-09-29 | 4 | PANOFF MARC L — Senior Vice President, Finance | Disposition to issuer (D): 3,944 (derivative) · Grant/award (A): 3,944 (derivative) · Disposition to issuer (D): 896 (derivative) · Grant/award (A): 896 (derivative) · Disposition to issuer (D): 1,255 (derivative) · Grant/award (A): 1,255 (derivative) · +5 more | EDGAR |
| 2025-09-16 | 4 | Pontifax Management 4 G.P. (2015) Ltd. — 10% owner | Conversion (C): 411,681 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 10,000,000 (derivative) | EDGAR |
| 2025-09-16 | 4 | Nussbaum Ran — Director | Conversion (C): 411,681 · Purchase (P): 1,000,000 @ $15 · Conversion (C): 10,000,000 (derivative) | EDGAR |
| 2025-09-16 | 4 | Deep Track Biotechnology Master Fund, Ltd. — 10% owner Deep Track Capital, LP — 10% owner KROIN DAVID — 10% owner | Conversion (C): 686,138 · Purchase (P): 2,000,000 @ $15 · Purchase (P): 666,666 @ $15 · Conversion (C): 16,666,667 (derivative) | EDGAR |
| 2025-09-16 | 4 | Vida Ventures GP III, L.L.C. — 10% owner Vida Ventures III, L.P. — 10% owner Vida Ventures III-A, L.P. — 10% owner Belldegrun Arie — 10% owner Vida Ventures Management Co. LLC — 10% owner | Conversion (C): 547,648 · Conversion (C): 1,262 · Purchase (P): 332,566 @ $15 · Purchase (P): 767 @ $15 · Conversion (C): 13,302,666 (derivative) @ $0 · Conversion (C): 30,667 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Hemrajani Rekha — Director | Grant/award (A): 22,449 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Luse Rebecca — Director | Grant/award (A): 22,449 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Kane William P Jr — Director | Grant/award (A): 22,449 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Silva Richard Anthony — SVP, Technical Operations | Disposition to issuer (D): 8,964 (derivative) · Grant/award (A): 8,964 (derivative) · Grant/award (A): 80,899 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Eramo Anna — Chief Medical Officer | Disposition to issuer (D): 26,893 (derivative) · Grant/award (A): 26,893 (derivative) · Disposition to issuer (D): 6,275 (derivative) · Grant/award (A): 6,275 (derivative) · Grant/award (A): 155,812 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Soffer Gad — Chief Business Officer | Disposition to issuer (D): 26,893 (derivative) · Grant/award (A): 26,893 (derivative) · Grant/award (A): 229,860 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Nussbaum Ran — Director | Grant/award (A): 22,449 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Garland J. Scott — Director | Disposition to issuer (D): 17,929 (derivative) · Grant/award (A): 17,929 (derivative) · Disposition to issuer (D): 3,585 (derivative) · Grant/award (A): 3,585 (derivative) · Grant/award (A): 22,449 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Turner Heather D — Chief Executive Officer, Director | Disposition to issuer (D): 175,706 (derivative) · Grant/award (A): 175,706 (derivative) · Disposition to issuer (D): 7,857 (derivative) · Grant/award (A): 7,857 (derivative) · Grant/award (A): 971,828 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | RUFFOLO ROBERT R — Director | Disposition to issuer (D): 1,792 (derivative) · Grant/award (A): 1,792 (derivative) · Disposition to issuer (D): 717 (derivative) · Grant/award (A): 717 (derivative) · Disposition to issuer (D): 10,757 (derivative) · Grant/award (A): 10,757 (derivative) · +1 more | EDGAR |
| 2025-09-12 | 4 | PRENSKY ZACHARY — Director | Disposition to issuer (D): 3,944 (derivative) · Grant/award (A): 3,944 (derivative) · Disposition to issuer (D): 896 (derivative) · Grant/award (A): 896 (derivative) · Disposition to issuer (D): 1,255 (derivative) · Grant/award (A): 1,255 (derivative) · +5 more | EDGAR |
Recent 8-K events — LB PHARMACEUTICALS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LBRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →